Close X
Friday, January 10, 2025
ADVT 
National

With Low Numbers Of New Cases, Ebola Vaccine Trials Fight Odds Of Success

The Canadian Press, 21 Jun, 2015 01:05 PM
    TORONTO — New Ebola infections in Guinea and Sierra Leone are down to a trickle. That means while there may still be time to prove if experimental Ebola vaccines protect against the dreaded disease, the chances of success are becoming slimmer.
     
    The teams trying to do that critical research know the odds are stacked against most of the trials that are underway.
     
    In fact, it could be that only one — a World Health Organization-led trial in Guinea testing a Canadian-designed vaccine — stands a real chance at coming up with an answer, if the case counts in West Africa continue at the current low level.
     
    The study involves vaccinating rings of people who are contacts of known cases to see if the vaccine prevents further spread. So far more than 70 rings out of a potential of 190 have been enrolled in the trial, testing a vaccine called rVSV-ZEBOV.
     
    Dr. Marie-Paule Kieny, who leads the WHO's efforts on development of Ebola vaccines and drugs, says if the vaccine is highly effective, the picture could come into focus relatively soon. The trial's independent overseers, its data and safety monitoring board, will be asked to review its status in the coming weeks.
     
    "So this is why it will be very important to let the DSMB at one point during summer ... look at the data and to tell us 'Well, you have enough' or 'Fine but keep going' or 'You will never demonstrate anything,'" Kieny says.
     
    If the trial proves rVSV-ZEBOV protects — or doesn't — and the outbreak still smoulders, the Guinea group will test a second vaccine. Kieny says work is underway to select which should be the second tested, a vaccine being developed by GSK or one being produced by Johnson and Johnson.
     
    Already a U.S. Centers for Disease Control-led trial in Sierra Leone has been adapted to ensure that it will produce useful information if, as feared, it cannot generate enough evidence to show whether the vaccine it is testing is effective.
     
    The Sierra Leone trial is also testing rVSV-ZEBOV, which was designed at Canada's National Microbiology Laboratory in Winnipeg. The vaccine is being developed by pharmaceutical giant Merck and NewLink Genetics, a biotech from Ames, Iowa.
     
    "It doesn't look very likely — although it's not impossible — that the trials will get at the efficacy of the vaccine," acknowledges Dr. Anne Schuchat, director of the CDC's Center for Immunization and Respiratory Diseases.
     
    The Sierra Leone trial to date has vaccinated more than 3,000 health-care professionals and other front-line Ebola response workers.
     
    In the event the trial can't reach a conclusion about the efficacy of the vaccine, the research team hopes to gather information that will help the U.S. Food and Drug Administration and other regulatory agencies consider another route to license the vaccine, called the animal rule.
     
    In exceptional circumstances when the efficacy of a drug or vaccine cannot be tested in people, regulators can substitute data from animal studies, pairing it with evidence that shows whether the product is safe to use.
     
    The Sierra Leone team will follow some of the people in their trial to see what happens to the levels of Ebola antibodies in their blood at various intervals post-vaccination.  
     
    "So we think it's too soon to be certain of whether (proving) efficacy will never be possible with our design," says Schuchat.
     
    "But we're trying to gather ... results that could potentially contribute to an alternate pathway to an accelerated licensure."
     
    A third trial testing rVSV-ZEBOV and the GSK vaccine started in Liberia early this year. Soon after Liberia's outbreak stopped, leaving that trial — led by the U.S. National Institute of Allergy and Infectious Diseases — unable to determine whether either vaccine works.
     
    Plans are being drawn up to move the trial to Guinea. But it's now estimated that the study will need to enrol roughly 200,000 people to prove if the vaccines work, given the low rate of new infections. The trial design is a classical one: Equal numbers of people will get one of the vaccines or a salt-water injection that will serve as a placebo.
     
    "I don't have a time frame but I'm hoping within one to two months we'd be able to start in Guinea," says Dr. Clifford Lane, clinical director for the National Institute for Allergy and Infectious Diseases. 
     
    Vaccinating that many people will take months, if not longer — a fact that leads some observers to question why the study is being pursued at this point.
     
    If the WHO study concludes by over the summer that rVSV-ZEBOV works, the new trial would have to be revised or abandoned. If it has been shown that one of the Ebola vaccines works, from an ethical point of view Ebola vaccines can no longer be studied against a placebo.
     
    As well, all involved in the Ebola outbreak hope transmission of the virus will be stopped long before this new study could get an answer.
     
    Lane understands that. Still, he says his group's approach is to push ahead until such time as it is clear the research cannot be done.
     
    "If in two months there are no cases that would be a great celebration," Lane says.
     
    "I'm being very serious. My hope is we never have to do this study. But as long as there's cases . . . we're going to work as hard as we can to get this launched."

    MORE National ARTICLES

    Court Hearing To Decide Whether $432-million Settlement For Victims Can Go Ahead

    Court Hearing To Decide Whether $432-million Settlement For Victims Can Go Ahead
    A Quebec Superior Court justice will begin hearing arguments Monday that could determine whether more than $431 million can be distributed to victims and creditors of the Lac-Megantic, Que.

    Court Hearing To Decide Whether $432-million Settlement For Victims Can Go Ahead

    Ex-Senate Reform Allies Mystified By PM's Seeming Lack Of Plan For Senate

    Ex-Senate Reform Allies Mystified By PM's Seeming Lack Of Plan For Senate
    The prime minister distanced himself from the damning revelations in last week's audit of senators' expenses, explaining that "the Senate is an independent 

    Ex-Senate Reform Allies Mystified By PM's Seeming Lack Of Plan For Senate

    Whale-Watching Guide: Orca Calf Spotted Near Tofino, B.C., Was Born This Week

    Whale-Watching Guide: Orca Calf Spotted Near Tofino, B.C., Was Born This Week
    TOFINO, B.C. — A newborn orca spotted off the coast of Tofino, B.C., looks healthy and adventurous, according to a whale-watching guide and researcher.

    Whale-Watching Guide: Orca Calf Spotted Near Tofino, B.C., Was Born This Week

    Ontario Premier Kathleen Wynne Suggests Regional Co-operation On Environment

    QUEBEC — The premiers of Quebec and Ontario are meeting with the governors of eight U.S. states today as part of a three-day conference on the future of the Great Lakes and St. Lawrence region.

    Ontario Premier Kathleen Wynne Suggests Regional Co-operation On Environment

    Crews Partly Contain Wildfire South Of Lytton, B.C., On Third Day Of Blaze

    Crews Partly Contain Wildfire South Of Lytton, B.C., On Third Day Of Blaze
    The B.C. Wildfire Management Branch says no significant growth in the fire occurred Saturday morning and the blaze is now about 12.8 square kilometres in size.

    Crews Partly Contain Wildfire South Of Lytton, B.C., On Third Day Of Blaze

    Jane Fonda Boosts Opposition To Kinder Morgan Trans Mountain Pipeline

    Jane Fonda Boosts Opposition To Kinder Morgan Trans Mountain Pipeline
    In 1970, Jane Fonda was arrested while marching with indigenous people. Forty-five years later, the Academy Award-winning actress says she's willing to be placed in handcuffs again while defending British Columbia's coast from oil tankers.

    Jane Fonda Boosts Opposition To Kinder Morgan Trans Mountain Pipeline